Breast Biopsy Devices Market In-Depth Analysis, Business Forecast and Dynamics 2024-2032

Breast Biopsy Devices Market Valuation – 2024-2031

Insurance coverage and government reimbursement policies for breast cancer diagnosis play an important role. Broader insurance coverage for breast biopsies makes the treatment more accessible to a wider patient population. The increasing government initiative and reimbursement policies are driving the growth of market size to surpass USD 2.12 Billion in 2024, to reach a valuation of USD 3.02 Billion by 2031.

The increased preference for minimally invasive techniques over standard surgical biopsies is a major motivator. Newer biopsy devices include smaller needles, shorter recovery times, and less discomfort for patients, making them an appealing option. The growing preference for minimally invasive procedures is enabling the market to grow at a CAGR of 4.50% from 2024 to 2031.

Breast Biopsy Devices Market: Definition/ Overview

A breast biopsy devices is a specialized medical instrument that extracts a tissue sample from the breast during a biopsy surgery. These devices are classified into numerous varieties based on the type of biopsy being conducted. The most common breast biopsy devices are core biopsy needles, fine needle aspiration needles, vacuum-assisted biopsy needles, stereotactic biopsy devices, and ultrasound probes. Breast biopsy devices need less invasive procedures, allowing doctors to obtain reliable diagnoses, and allowing them to adopt focused treatment strategies quickly. Biopsy technology is continually pushing the boundaries, providing improved accuracy, minimally invasive techniques, and rapid diagnosis.

Early detection is critical for successful treatment, and breast biopsy devices are the frontline troops in this battle. These specialized equipment serve an important role in obtaining tissue samples for diagnosis, allowing clinicians to execute tailored treatments. Several reasons are driving the growth of this market, including an increase in the number of breast cancer cases worldwide, increased public awareness of the need for early detection, and ongoing advancements in biopsy technology. This emphasis on minimally invasive procedures, improved accuracy, faster diagnosis, and increased patient comfort is creating a dynamic landscape for the Breast Biopsy Devices Market, with enormous potential for improved patient care, personalized medicine, and expansion into new markets in developing countries.

How the Rising Prevalence of Breast Cancer in Women and Growing Awareness of Breast Cancer is Driving the Growth of Breast Biopsy Devices?

The increasing prevalence of breast cancer globally is surging the growth of the breast biopsy market. Breast cancer is detected in women mostly in older age, with genetic mutations, dense breasts, and having any family history of breast cancer or ovarian cancer. According to the in 2022, 2.3 million women were diagnosed with breast cancer, and from that 670,000 died. Breast cancer is the most common cancer in women in 157 countries out of 185 in 2022. According to the , the breast cancer mortality rate is 2.5% per year. In addition, the increasing geriatric population is driving breast cancer in women, generally after menopause breast cancer is detected in women at the age of over 40 years. An increase in the geriatric population is one of the symptoms of breast cancer, in 2021 globally 761 million geriatric population. According to the in 2020 in Asia around 4.5 billion population are estimated to be geriatric.

The growing global awareness of breast cancer is driving up demand for breast cancer biopsy devices. Breast health awareness encompasses public and professional medical education on the dangers and symptoms of breast cancer, as well as the significance of medical evaluation for breast issues. Collaboration with cancer survivors, advocacy organizations, and community groups is critical for the effective design and dissemination of breast health awareness messaging. Breast cancer programs in low- and middle-income countries (LMICs) should adhere to a defined care pathway that takes into account available resources and capacities, allowing for coordinated incremental program development across the care continuum. Mammographic screening has been demonstrated to minimize breast cancer mortality in high-resource countries.

The technological advancement in cancer biopsy widely increasing and is highly adopted by professionals and developed countries. Positron emission tomography (PET) is used to measure the specific organ blood flow. It provides both functional and anatomical information, it analyzes the metastasis via lymph nodes more precisely than the conventional imaging. Computed tomography (CT) is used as a series of X-rays to take images of different angles. It scans quickly and has the potential to decrease motion artifacts, give accurate spatial information, and is used to construct digital radiographs. Magnetic resonance imaging (MRI) the contrast agent which is used in MRI is less likely to cause an allergic reaction compared to the iodine-based contrast agents. In addition, magnetic resonance spectroscopy (MRS) can give biological, physiological, anatomical, and metabolic information.

Also, the image-guided technologies are driving growth in the market. Breast biopsies are becoming more precise and efficient thanks to advances in image-guided technology like ultrasonography and stereotactic guidance systems. These advances allow for more precise targeting of questionable tissue samples, reducing the possibility of problems and the need for additional treatments. Mammotome or Vacora biopsies can be performed using ultrasound instead of a mammography. These techniques are comparable to stereotactic biopsy but include lying on your back with no compression or X-rays.

How the High Cost Associated with the Cancer Biopsy is Limiting the Growth of the Breast Biopsy Devices Market?

Advanced biopsy devices can be costly to purchase and operate. This can reduce accessibility, especially in areas with limited healthcare resources or for patients with limited insurance coverage. Biopsies cost between $307 for a tiny needle biopsy and $3,296 for a sophisticated surgical biopsy, with other biopsies costing $12,353. Mediastinum biopsies cost an average of $10,554. The cost of a vacuum-assisted biopsy is USD 264 per case.

The rise of liquid biopsy techniques, which study cancer cells in circulation, could provide a future challenge in the cancer biopsy device. Although not intended as a direct substitute, these non-invasive diagnostics may evolve into a screening tool, perhaps reducing the urgent need for tissue biopsies in certain situations. Liquid biopsies have the benefit of being less intrusive because they only entail the extraction of blood samples rather than tissue removal. As AI and digital technologies grow more common in biopsy instruments, data security is critical. With the possibility for sensitive patient information to be kept and exchanged online, strong cybersecurity safeguards are required. These safeguards aim to prevent unwanted access and data breaches, protect patient privacy, and ensure the integrity of medical data. As a result, healthcare institutions and device makers must invest in advanced security protocols and continuously upgrade their systems to combat new threats in the digital realm.

In addition, compliance with regulatory standards such as HIPAA (Health Insurance Portability and Accountability Act) is critical for maintaining patient confidentiality and trust in medical practices. By emphasizing data security, healthcare practitioners can confidently use AI and digital technologies to improve diagnostic accuracy and patient care while reducing the dangers of illegal access to sensitive medical information.

Category-Wise Acumens

How the Technological Advancements in the Biopsy Device Market are Driving the Growth of the Biopsy Needles Segment?

The biopsy needles segment is showing substantial growth in the Breast Biopsy Devices Market and is expected to continue its growth throughout the forecast period thanks to the technological advancements and the new product launches that are driving the growth of the biopsy needles segment in the market. The biopsy needle’s thin design allows for minimally invasive operations, which reduces patient discomfort, recuperation time, and complications. This minimally invasive nature also enables outpatient operations, which improves patient convenience. Versatility is another important asset.

Biopsy needles come in a variety of sizes, each designed to collect distinct types of tissue samples based on the location and characteristics of the suspicious area. Core biopsy needles extract bigger tissue cores for a thorough investigation, whereas fine-needle aspiration needles obtain a preliminary diagnosis from a smaller sample. Vacuum-assisted needles provide a compromise, gathering larger samples than ordinary core needles. Furthermore, biopsy needles are often less expensive than surgical biopsy equipment, making the treatment available to a wider spectrum of patients.

Also, many biopsy needles work perfectly with image-guided systems such as ultrasonography and stereotactic methods. This real-time imaging of targeted tissue increases sample collection accuracy and lowers the need for additional biopsies. To summarize, biopsy needles are a critical component of cancer biopsy equipment, offering a safe, effective, and cost-effective method of collecting tissue samples for accurate diagnosis.

How the Minimally Invasive Molecular Monitoring of Liquid Biopsy is Driving the Growth of the Breast Biopsy Devices Market?

The liquid Biopsy segment is significantly leading in the Breast Biopsy Devices Market. Liquid biopsy is an appealing option for cancer monitoring thanks to its low invasiveness. Unlike traditional tissue biopsies, which require intrusive procedures, liquid biopsy collects body fluids, typically peripheral blood, making it less stressful for patients. Liquid biopsy allows for the quantification of various genetic materials released into circulation by tumor cells, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA), circulating tumor RNA, extracellular vesicles (EVs), circulating tumor proteins, and tumor-educated platelets (TEPs). This extensive sampling yields a more complete picture of the tumor’s molecular composition.

Liquid biopsy has the advantage of being easier to serially evaluate than standard tissue biopsies. With liquid biopsy, practitioners can perform repeated tests over time with minimum discomfort to the patient, allowing for constant monitoring of disease progression and treatment response. Liquid biopsy, when paired with very sensitive molecular technology and modern bioinformatics techniques, can reveal intra-tumoral heterogeneity (spatial heterogeneity) as well as the molecular evolution of distant metastatic lesions. This is especially useful because standard tissue biopsies may not capture the entire spectrum of tumor cells found in heterogeneous tumors.

Unlike tissue biopsies, which may not accurately reflect the entire tumor, liquid biopsy provides a more comprehensive sampling of genetic elements generated by multiple tumor cells circulating in the bloodstream. This reduces the likelihood of non-representative biopsy specimens and gives a more accurate picture of the tumor’s genetic landscape.

Gain Access to Breast Biopsy Devices Market Report Methodology

Country/Region-wise Acumens

How will the Market Fare in North America?

North America is substantially dominating the Breast Biopsy Devices Market and is expected to continue its growth throughout the forecast period. Continuous technical improvements have fueled innovation in breast biopsy methods, resulting in more precise and minimally invasive approaches. These developments have enhanced diagnostic capabilities and patient outcomes, hence making breast biopsies more accessible and efficient. In addition, the rising incidence of breast cancer in North America has fueled the need for better diagnostic instruments and methods. According to the in the United States in 2020 239,612 breast cancer cases were registered and 42,273 females died in 2020 due to breast cancer. With increased awareness of breast health and early detection campaigns, there is a greater emphasis on the necessity of quick and correct diagnosis, which drives up demand for breast biopsy technology.

Favorable reimbursement conditions in the region have made breast biopsy procedures more accessible to patients. Healthcare regulations and insurance coverage schemes have facilitated the adoption of new diagnostic technology, encouraging both healthcare providers and patients to choose these operations. The new breast density notification rules in the United States have expanded the use of breast biopsy technologies. These regulations oblige healthcare providers to educate people about their breast density and the consequences of cancer detection, resulting in increased proactive screening methods and the use of modern biopsy techniques.

Competitive Landscape

The Breast Biopsy Devices Market is competitive and dynamic, with companies continuously striving to innovate and differentiate their offerings to meet the evolving needs of healthcare providers and patients. Collaboration with healthcare professionals and investment in research and development are key strategies for maintaining competitiveness in this rapidly advancing field.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Breast Biopsy Devices Market include:

• Aspen Surgical Products Company
• Deviceph
• INRAD
• Epredia
• Miltenyi Biotec
• Vacuumassister®
• IBreast Imaging Systems, Ltd.
• iGenomix
• EndoChoice, Inc.
• Endosight Corporation

Report Scope

Breast Biopsy Devices Market, By Category

Type:

• Biopsy Needles
• Guidance Systems
• Biopsy Tables
• Localization Wires
• Assay Kits

Procedure:

• Needle Breast Biopsy
• Open Surgical Breast Biopsy
• Liquid Breast Biopsy

Technique:

• Image Guided Biopsy
• Liquid Biopsy

Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.